Floatz logo

Rifaximin

Metabolic-associated Fatty Liver Disease

Shanghai Changzheng HospitalSmall moleculePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

139 Active assets in the Metabolic-associated Fatty Liver Disease cohort.

Asset / SponsorPhaseRating
Dapagliflozin
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 4BBB
Empagliflozin
Justin Ryder
Phase 4BBB
Exenatide
Fudan University
Phase 4BBB
Metformin
Xiqiao Zhou
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB

View all 50 →

Same molecule, other indications

Rifaximin is also rated in:

hepatic encephalopathyDormant
BBB
Indicative ·
75 / 100
View asset →
cirrhosis of liverDormant
BBB
Indicative ·
72 / 100
View asset →
AscitesDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →